Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 4Lung Neoplasms 4Prostatic Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumors 3Urinary Bladder Neoplasms 2Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Head and Neck Neoplasms 2Biliary Tract Neoplasms 2Urothelial Cancer 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1

Interventions

Injections 12pembrolizumab 11Nivolumab 9Paclitaxel 8senaparib 7Docetaxel 7Cisplatin 6Capecitabine 6Gemcitabine 5toripalimab 4tislelizumab 4atezolizumab 4Ipilimumab 4Carboplatin 4Bevacizumab 4sintilimab 3Rifampin 3Oxaliplatin 3Itraconazole 3130-nm albumin-bound paclitaxel 3zimberelimab 2pertuzumab 2osimertinib 2ontuxizumab 2navoximod 2magrolimab 2fluzoparib 2famitinib 2durvalumab 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor × tremelimumab × Clear all
NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
72 enrolled 23 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡